Propanc Biopharma Inc (PPCB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Propanc Biopharma Inc (PPCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12384
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Propanc Biopharma Inc (Propanc), formerly Propanc Health Group Corp, is a clinical stage biopharmaceutical company, which manufactures products for the treat of metastatic, pancreatic, ovarian and colorectal cancers. The company’s lead product candidate, PRP, a once-a-day intravenous formulation of two pancreatic proenzymes, trypsinogen and chymotrypsinogen, helps block the recurrence of tumor and metastasis. PRP curtails tumor growth by curbing cancer cell migration and suppressing tumor blood vessel formation, and ultimately causing cell death. The company works in collaboration with other research universities and companies including University of Grenada, Universidad de Jaen, University of Bath and vivoPharm Pty Ltd for the research and development of PRP. Propanc is headquartered in Melbourne, Victoria, Australia.

Propanc Biopharma Inc (PPCB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Propanc Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Propanc Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Propanc Health Raises US$0.03 Million In Venture Financing 12
Partnerships 13
Propanc Biopharma Enters into Research Agreement with University of Jaen 13
Propanc Biopharma Enters into Research Partnership with Jaen University 14
Equity Offering 15
Propanc Health to Raise Funds through Public Offering of Shares and Warrants 15
Propanc Biopharma Raises USD0.2 Million in Private Placement of Shares, up on Exercise of Warrants 16
Propanc Biopharma Raises USD0.3 Million in Private Placement of Shares, up on Exercise of Warrants 17
Propanc Health to Raise USD0.02 Million in Private Placement of Shares 18
Propanc Health to Raise Funds through Private Placement of Shares 19
Propanc Health Raises Funds through Private Placement of Shares 20
Propanc Health to Raise USD5 Million in Private Placement of Shares 21
Propanc Health Announces Private Placement of Shares For US$1.5 Million 22
Debt Offering 23
Propanc Biopharma Raises USD0.4 Million in Private Placement of Debt Securities 23
Propanc Biopharma Raises USD6.31 Million in Debt Offering of Notes 24
Propanc Biopharma Raises USD0.22 Million in Private Placement of 8% Notes 25
Propanc Biopharma Raises USD0.23 Million in Private Placement of 8% Notes 26
Propanc Biopharma Raises USD0.17 Million in Private Placement of 8% Convertible Notes 27
Propanc Biopharma Raises USD0.1 Million in Private Placement of 8% Convertible Notes 28
Propanc Biopharma Raises USD0.1 Million in Private Placement of 8% Notes 29
Propanc Health Raises USD4 Million in Private Placement of Debenture 30
Propanc Biopharma Inc – Key Competitors 31
Propanc Biopharma Inc – Key Employees 32
Propanc Biopharma Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Corporate Communications 34
Jan 10, 2018: Propanc Biopharma Engages Alan Morell of Creative Management Partners as Senior Strategic Advisor to CEO and Board of Directors 34
Product News 35
Dec 04, 2017: Propanc Biopharma Advances towards GMP Manufacture of PRP for Human Trials 35
05/19/2017: Propanc Biopharma Highlights PRP’s Potential to Reprogram Cancer Stem Cells 36
05/02/2017: Propanc Biopharma Provides Update on Investigational Medicinal Product Manufacture of PRP for First-In-Human Studies 37
02/14/2017: Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study 38
01/04/2017: Propanc Provides Shareholder Update and Forecast for 2017 39
Clinical Trials 41
Apr 27, 2017: Propanc Successfully Completes 28-Day Repeat-Dose Toxicity Study for PRP 41
Other Significant Developments 42
Feb 12, 2018: Propanc Biopharma Provides Shareholder Update and Goals for 2018 42
Mar 31, 2017: Propanc Announces Name Change to Propanc Biopharma 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Propanc Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Propanc Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Propanc Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Propanc Health Raises US$0.03 Million In Venture Financing 12
Propanc Biopharma Enters into Research Agreement with University of Jaen 13
Propanc Biopharma Enters into Research Partnership with Jaen University 14
Propanc Health to Raise Funds through Public Offering of Shares and Warrants 15
Propanc Biopharma Raises USD0.2 Million in Private Placement of Shares, up on Exercise of Warrants 16
Propanc Biopharma Raises USD0.3 Million in Private Placement of Shares, up on Exercise of Warrants 17
Propanc Health to Raise USD0.02 Million in Private Placement of Shares 18
Propanc Health to Raise Funds through Private Placement of Shares 19
Propanc Health Raises Funds through Private Placement of Shares 20
Propanc Health to Raise USD5 Million in Private Placement of Shares 21
Propanc Health Announces Private Placement of Shares For US$1.5 Million 22
Propanc Biopharma Raises USD0.4 Million in Private Placement of Debt Securities 23
Propanc Biopharma Raises USD6.31 Million in Debt Offering of Notes 24
Propanc Biopharma Raises USD0.22 Million in Private Placement of 8% Notes 25
Propanc Biopharma Raises USD0.23 Million in Private Placement of 8% Notes 26
Propanc Biopharma Raises USD0.17 Million in Private Placement of 8% Convertible Notes 27
Propanc Biopharma Raises USD0.1 Million in Private Placement of 8% Convertible Notes 28
Propanc Biopharma Raises USD0.1 Million in Private Placement of 8% Notes 29
Propanc Health Raises USD4 Million in Private Placement of Debenture 30
Propanc Biopharma Inc, Key Competitors 31
Propanc Biopharma Inc, Key Employees 32
Propanc Biopharma Inc, Subsidiaries 33

List of Figures
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Propanc Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Propanc Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Propanc Biopharma Inc (PPCB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • numares AG:企業の製品パイプライン分析2018
    Summary Numares AG (Numares), formerly Numares GmbH, is a developer and marketer of products for life science research and clinical diagnostics. The company’s AXINON lipoFIT, a test system used for lipoprotein profiling, while insightLP provides insights into lipid related research using lipoprotein …
  • Celgene Corporation:企業の戦略・SWOT・財務情報
    Celgene Corporation - Strategy, SWOT and Corporate Finance Report Summary Celgene Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Juhl Energy Inc:企業の戦略的SWOT分析
    Juhl Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Scottish and Southern Energy plc:企業の戦略・SWOT・財務情報
    Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report Summary Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Interconexion Electrica SA ESP (ISA):企業の財務・戦略的SWOT分析
    Interconexion Electrica SA ESP (ISA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • United International Enterprises Limited:企業の戦略・SWOT・財務情報
    United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Loews Corp:企業の戦略・SWOT・財務情報
    Loews Corp - Strategy, SWOT and Corporate Finance Report Summary Loews Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Nippon Flour Mills Co Ltd (2001):企業の財務・戦略的SWOT分析
    Nippon Flour Mills Co Ltd (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Tufts University-製薬・医療分野:企業M&A・提携分析
    Summary Tufts University (Tufts) is an educational and research university that offers undergraduate and postgraduate courses in various fields. The university offer courses in anthropology, applied mathematics, architectural engineering, physics, archaeology, Asian American studies, biochemistry, b …
  • Valeant Pharmaceuticals International, Inc.:企業のM&A・事業提携・投資動向
    Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Valeant Pharmaceuticals International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • China Medical System Holdings Ltd (867):製薬・医療:M&Aディール及び事業提携情報
    Summary China Medical System Holdings Ltd (CMS) is a pharmaceutical service provider that markets, promotes, and sells prescription drugs to all therapeutic departments in hospitals. The company offers products such as deanxit, ursofalk, augentropfen stulln mono eye-drops, exacin, xinhuosu, salofalk …
  • Trimedyne Inc:企業の戦略的SWOT分析
    Trimedyne Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Kyokuyo Co., Ltd.
    Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • East Japan Railway Co:企業の戦略・SWOT・財務分析
    East Japan Railway Co - Strategy, SWOT and Corporate Finance Report Summary East Japan Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Puma Energy Holdings Pte Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Puma Energy Holdings Pte Ltd (Puma Energy) is an integrated midstream and downstream energy company. Its midstream operations include the supply, storage and transportation of petroleum products. The company’s downstream operations include the distribution, retail sales and wholesale of a wi …
  • Dana Inc:企業の戦略・SWOT・財務分析
    Dana Inc - Strategy, SWOT and Corporate Finance Report Summary Dana Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Planmeca Oy:企業の戦略的SWOT分析
    Planmeca Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Intercede Group plc (IGP):企業の財務・戦略的SWOT分析
    Intercede Group plc (IGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Provogue (India) Limited (PROVOGE):企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Caris Life Sciences Inc:企業の製品パイプライン分析
    Summary Caris Life Sciences Inc (Caris Life) is a biotechnology company. The company’s molecular scientific offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make personalized treatment decisions. Its ADAPT biotargeting system, is a plat …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆